Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

NeuroPace Earnings Call: Key Takeaways

NeuroPace reported a disappointing Q3 with revenue declining 1.1% year-over-year, leading to a significant full-year guidance cut due to salesforce disruption and operational issues at major accounts.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthR&S revenue grew 1.4% to $22.9M; service revenue fell to $203k.
Mgmt ConfidenceAccountable for shortfall; taking 'prudent' approach to Q4 and 2027 recovery.
Demand VisibilitySix to nine-month patient pathway; seeing recovery in large accounts in Q4.
Margin TrendsAdjusted gross margin 84.8%, up 200 bps due to labor absorption.
Op. LeverageAdjusted OPEX decreased 7% to $19.2M; managing spending while investing commercially.
Pricing PowerCMS increased hospital outpatient payment rate for R&S replacements by 11%.
Vol vs PriceGrowth impacted by procedural scheduling delays and staffing issues at centers.
Segment GrowthR&S system revenue $22.9M; service revenue $0.2M.
New ClientsReached new high in active prescribers; expanding medium-sized 'good to great' accounts.
Capex & DebtEnded quarter with $49.5M cash; long-term borrowings total $59.2M.
RegulatoryIGE PMA amendment submission by year-end; potential approval mid-2027.
CommentaryStrategic shift from SEEG distribution caused temporary loss of routine OR presence.
New LaunchesRemote care submitted to FDA; Aurora study for adolescent focal epilepsy initiated.

Growth

Total revenue $23.1M, down 1.1%; R&S system revenue $22.9M, up 1.4% year-over-year.

Outlook

Guiding 2027 R&S revenue growth to 15%, accelerating to 20% exit rate.

Risks

Management pivoted to 'local market factors' when pressed on competition and customer concentration risks.

Source

The company's earnings call, NASDAQ: NPCE, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

NeuroPace Inc: key numbers

Share price
$7.97Close, Nov 16
Market cap
$275M
Shares outstanding
34.45MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from NeuroPace Inc

All →
4:39 PM ET 10-Q
Financial Results ▶ Call

NeuroPace Q3 2026 Results: Net Loss of $3.3M, Loss Narrows

NeuroPace reported a decrease in total assets from $105.6 million at the end of 2025 to $94.8 million as of September 30, 2026, primarily driven by a reduction in cash and short-term investments. The company maintains a significant accumulated deficit of $568.6 million and expects to lose its emerging growth company status on December 31, 2026.

Key figure
Net loss $3.3M
4:09 PM ET 8-K
Financial Results

NeuroPace Financial Results

NeuroPace reported Q3 2026 total revenue of $23.1 million, missing internal expectations due to commercial execution issues and field organization disruption. The company revised its full-year 2026 revenue guidance downward to $91-$92 million while advancing its innovation pipeline, including an FDA submission for NeuroPace Remote Care.

Term
Q3 2026

“Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to historical growth rates. The shortfall was concentrated in several of our largest accounts and reflected isolated account-level issues and changes to our field organization that created more disruption than anticipated.”

Joel Becker, President and Chief Executive Officer of NeuroPace

“Our innovation pipeline represents one of the most significant opportunities ahead for NeuroPace, combining potential indication expansion with capabilities that can make RNS therapy more accessible, efficient and personalized.”

Joel Becker, President and Chief Executive Officer of NeuroPace

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.